biosimilars

News

Merck & Co spin off could start a trend in big pharma

Merck & Co’s strategy to spin off its older drugs and biosimilars into a new stand-alone business will be closely watched by other pharma companies considering the same move, analysts h

Views & Analysis

3 key trends shaping the immunology market

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.

Views & Analysis

5-years-of-biosimilars-in-the-US-Industry-Pulse

5 years of biosimilars in the US: what have we learned?

Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide.

Partner Content

Partner Content

J+D Forecasting launches innovative pharmaceutical sales for...

Sales+ is the first Excel add-in that provides all the

News

Pfizer launches biosimilars to Roche's 'big three' cancer dr...

Pfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at a “substantially discounted price” compared with the originators.

Partner Content